uric acid has been researched along with Menopause in 53 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Equol producer status was associated with favorable metabolic parameters, in women in the early phase postmenopause, with the transitional periods noted with declining intrinsic estrogen levels." | 7.85 | Relationship between equol producer status and metabolic parameters in 743 Japanese women: equol producer status is associated with antiatherosclerotic conditions in women around menopause and early postmenopause. ( Myint, KZ; Ohta, H; Yoshikata, R, 2017) |
| "Uric acid, the levels of which have been shown to increase after menopause, has been associated with metabolic syndrome." | 7.77 | Relationship between uric acid and metabolic syndrome according to menopausal status. ( Ahn, KH; Cho, GJ; Hur, JY; Kim, SH; Kim, T; Kim, YT; Lee, HJ; Park, HT; Shin, JH; Yi, KW, 2011) |
| " We evaluated and quantified the potential independent association between menopause, postmenopausal hormone use and serum uric acid levels in a nationally representative sample of women." | 7.74 | Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey. ( Choi, HK; Hak, AE, 2008) |
| "We reviewed the clinical features and uric acid metabolism in 37 female patients with gout." | 7.68 | Female gout. Clinical spectrum and uric acid metabolism. ( Capitán, CF; de Miguel, E; Gijón, JB; Jiménez, ML; Mateos, FA; Michán, AD; Pérez de Ayala, C; Puig, JG, 1991) |
| "The uric acid concentration was significantly higher in postmenopausal versus premenopausal women." | 6.69 | The effect of menopause on serum uric acid levels in non-obese healthy women. ( Stevenson, JC; Walton, C; Wingrove, CS, 1998) |
| "Menopause may be a crucial factor related to changes in serum total cholesterol, non-high-density lipoprotein cholesterol, triglycerides, uric acid, hemoglobin, and liver enzymes." | 4.31 | Changes in cardiovascular disease risk factors during menopausal transition in Japanese women: the Circulatory Risk in Communities Study (CIRCS). ( Cui, R; Hayama-Terada, M; Imano, H; Iso, H; Kihara, T; Kitamura, A; Kiyama, M; Muraki, I; Ohira, T; Okada, T; Sankai, T; Shimizu, Y; Tanaka, M; Teramura, S; Umesawa, M; Yamagishi, K, 2023) |
| "Elevated serum uric acid (SUA)-hyperuricemia-is caused by overproduction of urate or by its decreased renal and/or intestinal excretion." | 4.02 | Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach. ( Ayaori, M; Harada-Shiba, M; Higashino, T; Hishida, A; Ikewaki, K; Kawai, S; Kawamura, Y; Matsuo, H; Naito, M; Nakajima, M; Nakayama, A; Ogura, M; Okada, R; Sakiyama, M; Sasaki, M; Shimizu, S; Shinomiya, N; Suzuki, H; Takada, T; Takata, K; Toyoda, Y; Yamanashi, Y, 2021) |
| "Equol producer status was associated with favorable metabolic parameters, in women in the early phase postmenopause, with the transitional periods noted with declining intrinsic estrogen levels." | 3.85 | Relationship between equol producer status and metabolic parameters in 743 Japanese women: equol producer status is associated with antiatherosclerotic conditions in women around menopause and early postmenopause. ( Myint, KZ; Ohta, H; Yoshikata, R, 2017) |
| "Uric acid, the levels of which have been shown to increase after menopause, has been associated with metabolic syndrome." | 3.77 | Relationship between uric acid and metabolic syndrome according to menopausal status. ( Ahn, KH; Cho, GJ; Hur, JY; Kim, SH; Kim, T; Kim, YT; Lee, HJ; Park, HT; Shin, JH; Yi, KW, 2011) |
| " The effect of factors such as age, gender, body mass index, alcohol and tobacco consumption, menopause, drug intake, trace elements, transferrin, ferritin, albumin, bilirubin, haptoglobin, total proteins, uric acid, haemoglobin, and mean corpuscular volume of erythrocytes have been studied for the three antioxidant markers." | 3.72 | Serum total antioxidant status, erythrocyte superoxide dismutase and whole-blood glutathione peroxidase activities in the Stanislas cohort: influencing factors and reference intervals. ( Fitzgerald, PS; Habdous, M; Herbeth, B; Lamont, JV; Siest, G; Vincent-Viry, M; Visvikis, S, 2003) |
| "To determine the effect of aging on renal functions, I measured the concentration of blood urea nitrogen (BUN), serum uric acid and serum creatinine." | 3.69 | [The effects of aging on renal function test]. ( Yoshida, K, 1994) |
| "We reviewed the clinical features and uric acid metabolism in 37 female patients with gout." | 3.68 | Female gout. Clinical spectrum and uric acid metabolism. ( Capitán, CF; de Miguel, E; Gijón, JB; Jiménez, ML; Mateos, FA; Michán, AD; Pérez de Ayala, C; Puig, JG, 1991) |
| " A number of antecedent metabolic risk factors proved atherogenic, including blood lipids, glucose tolerance, uric acid, and menopause." | 3.67 | Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. ( Kannel, WB, 1987) |
| "The uric acid concentration was significantly higher in postmenopausal versus premenopausal women." | 2.69 | The effect of menopause on serum uric acid levels in non-obese healthy women. ( Stevenson, JC; Walton, C; Wingrove, CS, 1998) |
| "Uric acid metabolism was studied in groups of early post-menopausal women before and during long-term administration of natural oestrogen/gestagen (n = 21), bendroflumethiazide (n = 19) or placebo (n = 34)." | 2.65 | Effect of natural oestrogen/gestagen therapy on uric acid metabolism in post-menopausal women. ( Christiansen, C; Gotfredsen, A; Transbøl, I, 1983) |
| "In this study, type 2 diabetes (T2D), sex, and menopausal status were combined to refine the stratification of obesity regarding the risk of advanced SLD and gain further insight into disease physiopathology." | 1.91 | Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study. ( Baud, G; Bauvin, P; Caiazzo, R; Chatelain, E; Chetboun, M; Gnemmi, V; Lasailly, G; Lefebvre, P; Legendre, B; Leteurtre, E; Marciniak, C; Marot, G; Mathurin, P; Oukhouya-Daoud, N; Pattou, F; Raverdy, V; Staels, B; Vandel, J; Vantyghem, MC; Verkindt, H, 2023) |
| "Hyperuricemia was defined as SUA higher than 360μmol/L (approximately 6 mg/dl)." | 1.72 | The Mediation Effect of Body Composition on the Association Between Menopause and Hyperuricemia: Evidence From China National Health Survey. ( Cui, Z; Du, J; He, H; Liu, F; Pa, L; Pan, L; Peng, X; Ren, X; Shan, G; Wang, D; Wang, H; Wang, X; Wang, Y; Yu, C; Zhao, J, 2022) |
| "Uric acid levels were tested by the uricase method." | 1.38 | Reproductive factors and serum uric acid levels in females from the general population: the KORA F4 study. ( Belcredi, P; Döring, A; Heier, M; Meisinger, C; Stöckl, D; Thorand, B, 2012) |
| "The insulin resistance is associated with a clustering of risk factors of cardiovascular disease, more cluste-ring, more resistant." | 1.30 | [The role of insulin resistance in the clustering of cardiovascular risk factors]. ( Guo, D; Xu, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (41.51) | 18.7374 |
| 1990's | 8 (15.09) | 18.2507 |
| 2000's | 7 (13.21) | 29.6817 |
| 2010's | 10 (18.87) | 24.3611 |
| 2020's | 6 (11.32) | 2.80 |
| Authors | Studies |
|---|---|
| Ogura, M | 1 |
| Toyoda, Y | 1 |
| Sakiyama, M | 1 |
| Kawamura, Y | 1 |
| Nakayama, A | 1 |
| Yamanashi, Y | 1 |
| Takada, T | 1 |
| Shimizu, S | 1 |
| Higashino, T | 1 |
| Nakajima, M | 1 |
| Naito, M | 1 |
| Hishida, A | 1 |
| Kawai, S | 1 |
| Okada, R | 1 |
| Sasaki, M | 1 |
| Ayaori, M | 1 |
| Suzuki, H | 1 |
| Takata, K | 1 |
| Ikewaki, K | 1 |
| Harada-Shiba, M | 1 |
| Shinomiya, N | 1 |
| Matsuo, H | 1 |
| Desfita, S | 1 |
| Sari, W | 1 |
| Yusmarini, Y | 1 |
| Pato, U | 1 |
| Zakłos-Szyda, M | 1 |
| Budryn, G | 1 |
| He, H | 1 |
| Pan, L | 1 |
| Liu, F | 1 |
| Ren, X | 1 |
| Cui, Z | 1 |
| Pa, L | 1 |
| Zhao, J | 1 |
| Wang, D | 1 |
| Du, J | 1 |
| Wang, H | 1 |
| Wang, X | 1 |
| Peng, X | 1 |
| Yu, C | 1 |
| Wang, Y | 1 |
| Shan, G | 1 |
| Teramura, S | 1 |
| Sankai, T | 1 |
| Yamagishi, K | 1 |
| Umesawa, M | 1 |
| Hayama-Terada, M | 1 |
| Muraki, I | 1 |
| Tanaka, M | 1 |
| Kihara, T | 1 |
| Ohira, T | 1 |
| Imano, H | 1 |
| Cui, R | 1 |
| Shimizu, Y | 1 |
| Okada, T | 1 |
| Kitamura, A | 1 |
| Kiyama, M | 1 |
| Iso, H | 1 |
| Cota E Souza, LA | 1 |
| D'Angelo, GCO | 1 |
| da Silva, GN | 1 |
| Lima, AA | 1 |
| Raverdy, V | 1 |
| Chatelain, E | 1 |
| Lasailly, G | 1 |
| Caiazzo, R | 1 |
| Vandel, J | 1 |
| Verkindt, H | 1 |
| Marciniak, C | 1 |
| Legendre, B | 1 |
| Bauvin, P | 1 |
| Oukhouya-Daoud, N | 1 |
| Baud, G | 1 |
| Chetboun, M | 1 |
| Vantyghem, MC | 1 |
| Gnemmi, V | 1 |
| Leteurtre, E | 1 |
| Staels, B | 1 |
| Lefebvre, P | 1 |
| Mathurin, P | 1 |
| Marot, G | 1 |
| Pattou, F | 1 |
| Lee, SH | 1 |
| Kim, KM | 1 |
| Kim, KN | 1 |
| Cortese, M | 1 |
| Riise, T | 1 |
| Engeland, A | 1 |
| Ascherio, A | 1 |
| Bjørnevik, K | 1 |
| Ishii, S | 1 |
| Miyao, M | 1 |
| Mizuno, Y | 1 |
| Tanaka-Ishikawa, M | 1 |
| Akishita, M | 1 |
| Ouchi, Y | 1 |
| Krishnan, E | 1 |
| Bennett, M | 1 |
| Chen, L | 1 |
| Bonaccorsi, G | 1 |
| Romani, A | 1 |
| Cremonini, E | 1 |
| Bergamini, CM | 1 |
| Castaldini, MC | 1 |
| Fila, E | 1 |
| Hanau, S | 1 |
| Massari, L | 1 |
| Cervellati, C | 1 |
| Yoshikata, R | 1 |
| Myint, KZ | 1 |
| Ohta, H | 1 |
| Hak, AE | 1 |
| Choi, HK | 1 |
| Gaffo, AL | 1 |
| Saag, KG | 1 |
| McClory, J | 1 |
| Said, N | 1 |
| Ogbera, A | 1 |
| Fasanmade, O | 1 |
| Kalra, S | 1 |
| Lee, HJ | 1 |
| Park, HT | 1 |
| Cho, GJ | 1 |
| Yi, KW | 1 |
| Ahn, KH | 1 |
| Shin, JH | 1 |
| Kim, T | 1 |
| Kim, YT | 1 |
| Hur, JY | 1 |
| Kim, SH | 1 |
| Stöckl, D | 1 |
| Döring, A | 1 |
| Thorand, B | 1 |
| Heier, M | 1 |
| Belcredi, P | 1 |
| Meisinger, C | 1 |
| Ioannou, GN | 1 |
| Boyko, EJ | 1 |
| Habdous, M | 1 |
| Herbeth, B | 1 |
| Vincent-Viry, M | 1 |
| Lamont, JV | 1 |
| Fitzgerald, PS | 1 |
| Visvikis, S | 1 |
| Siest, G | 2 |
| BYWATERS, EG | 1 |
| HOLLOWAY, VP | 1 |
| Solov'eva, OA | 1 |
| Balkarov, IM | 1 |
| Smetnik, VP | 1 |
| Eliseeva, NA | 1 |
| Lebedeva, MV | 1 |
| Shovskaia, TN | 1 |
| Aleksandrovskaia, TN | 1 |
| Gotfredsen, A | 1 |
| Christiansen, C | 1 |
| Transbøl, I | 1 |
| Taddeo, A | 2 |
| Renieri, A | 2 |
| Fioravanti, A | 2 |
| Morozzi, G | 2 |
| Parrini, E | 1 |
| D'Amato, MS | 2 |
| Ricci, MG | 1 |
| Beitins, IZ | 1 |
| Shah, A | 1 |
| O'Loughlin, K | 1 |
| Johnson, L | 1 |
| Ostrea, TR | 1 |
| Van Wart, J | 1 |
| McArthur, JW | 1 |
| Steinmetz, J | 1 |
| Panek, E | 1 |
| Okada, M | 1 |
| Takeshita, M | 1 |
| Ueda, K | 1 |
| Omae, T | 1 |
| Hirota, Y | 1 |
| Yoshida, K | 1 |
| Peh, CA | 1 |
| Horowitz, M | 1 |
| Wishart, JM | 1 |
| Need, AG | 1 |
| Morris, HA | 1 |
| Nordin, BE | 1 |
| Nilsson, P | 1 |
| Möller, L | 1 |
| Köster, A | 1 |
| Hollnagel, H | 1 |
| Wingrove, CS | 1 |
| Walton, C | 1 |
| Stevenson, JC | 1 |
| Guo, D | 1 |
| Xu, C | 1 |
| Park, YB | 1 |
| Park, YS | 1 |
| Song, J | 1 |
| Lee, WK | 1 |
| Suh, CH | 1 |
| Lee, SK | 1 |
| Garrapa, GG | 1 |
| Pantanetti, P | 1 |
| Arnaldi, G | 1 |
| Mantero, F | 1 |
| Faloia, E | 1 |
| Shibata, H | 1 |
| Matsuzaki, T | 1 |
| Hatano, S | 1 |
| Adamopoulos, D | 1 |
| Vlassopoulos, C | 1 |
| Seitanides, B | 1 |
| Contoyiannis, P | 1 |
| Vassilopoulos, P | 1 |
| Harris, EK | 1 |
| Kotake, H | 1 |
| Sawada, Y | 1 |
| Hoshio, A | 1 |
| Shirota, K | 1 |
| Tomokuni, A | 1 |
| Doi, T | 1 |
| Hisatome, I | 1 |
| Mashiba, H | 1 |
| Puig, JG | 1 |
| Michán, AD | 1 |
| Jiménez, ML | 1 |
| Pérez de Ayala, C | 1 |
| Mateos, FA | 1 |
| Capitán, CF | 1 |
| de Miguel, E | 1 |
| Gijón, JB | 1 |
| Armellini, F | 1 |
| Micciolo, R | 1 |
| Ferrari, P | 1 |
| Zamboni, M | 1 |
| Gottardi, L | 1 |
| Cavallo, E | 1 |
| Bosello, O | 1 |
| Menon, RK | 1 |
| Okonofua, FE | 1 |
| Agnew, JE | 1 |
| Thomas, M | 1 |
| Bell, J | 1 |
| O'Brien, PM | 1 |
| Dandona, P | 1 |
| Kannel, WB | 1 |
| Marcolongo, R | 1 |
| Lally, EV | 1 |
| Ho, G | 1 |
| Kaplan, SR | 1 |
| Antón, FM | 1 |
| García Puig, J | 1 |
| Ramos, T | 1 |
| González, P | 1 |
| Ordás, J | 1 |
| Babucke, G | 1 |
| Mertz, DP | 1 |
| Wilding, P | 1 |
| Rollason, JG | 1 |
| Robinson, D | 1 |
| Blahos, J | 1 |
| Vojtisek, O | 1 |
| Kanková, D | 1 |
| Krízek, V | 1 |
| Griebsch, A | 1 |
| Zöllner, N | 1 |
| Eastwood, MR | 1 |
| Trevelyan, H | 1 |
| Schilling, A | 1 |
| Emmerson, BT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism[NCT01990560] | Phase 4 | 8 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of Urate After a Single Dose of Inosine in Healthy Male Subjects[NCT02614469] | Phase 1 | 18 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in hyperglycemia assessed by HbA1c, also known as glycated hemoglobin (NCT01990560)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | percentage of red blood cells (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | 6 months | |
| Mifepristone | 6.2 | 6.1375 | 6.125 |
Change in metabolic syndrome as assessed by BMI (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | kg/m2 (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 35.1538 | 34.5463 |
Change in Quality of Life - as assessed by the Cushing's Quality of Life questionnaire (CushingQoL). Patient completed questionnaire, 12 items, each scored on a 5 point score, resulting in a score of 12 (worst) to 60 (best) where higher scores indicate more favorable QOL. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 37.2857 | 38.7857 |
Change in metabolic syndrome as assessed by fasting lipid profile which includes Low-density lipoproteins ( LDL), High-density lipoproteins (HDL), and Triglycerides (Trigs) levels, and total cholesterol which is the sum of HDL plus LDL and 20% of trigs. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total Cholesterol Baseline | Total Cholesterol 6 months | LDL baseline | LDL 6 months | HDL Baseline | HDL 6 months | Trigs Baseline | Trigs 6 months | |
| Mifepristone | 178.63 | 171.43 | 97.88 | 104.37 | 59.13 | 46.86 | 107.88 | 100.29 |
Change in hyperglycemia assessed by Homeostatic Model Assessment of Insulin Resistance, HOMA-IR (a validated assessment of insulin resistance). HOMA-IR = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | HOMA-IR score (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 2.418 | 1.465 |
Change in Quality of Life as assessed by the Hospital Anxiety and Depression Scale (HADS). Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 16.2857 | 11.1667 |
Change in Quality of Life as assessed by the Nottingham Health Profile (NHP) which is a patient reported questionnaire to measure a patient's view of their own health status. There are 6 sections (Energy level, Pain, Emotional Reaction, Sleep, Social Isolation, and Physical Abilities. All questions have only yes/no answer options and each section score is weighted so that the possible score range for any section is 0-100. The higher the score, the greater the number and severity of problems. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Energy Level (EL) Baseline | EL 6 months | Pain (P) Baseline | P 6 months | Emotional Reaction (ER) Baseline | ER 6 months | Sleep (S) Baseline | S 6 months | Social Isolation (SI) Baseline | SI 6 months | Physical Abilities (PA) Baseline | PA 6 months | |
| Mifepristone | 32.60 | 45.40 | 24.88 | 32.08 | 27.03 | 35.09 | 24.87 | 31.15 | 20.09 | 31.15 | 23.06 | 27.49 |
Change in Quality of Life as assessed by the Beck Depression Inventory. a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 16.1429 | 11.7143 |
Change in Quality of Life - as assessed by the State Trait Anxiety Inventory (STAI). The State-Trait Anxiety Inventory both state and trait anxiety separately. Each type of anxiety has its own scale of 20 different questions that are scored and averaged. Total scores range from 20 to 80, with higher scores correlating with greater anxiety. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 25.4286 | 28.8571 |
Change in metabolic syndrome as assessed by waist circumference (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 103.25 | 99.3125 |
Change in metabolic syndrome as assessed by weight (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | kg (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 99.57 | 97.75 |
(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 2040 |
| Inosine Fasted | 2031 |
(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 267 |
| Inosine Fasted | 268 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 80.4 |
| Inosine Fasted | 83.0 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg*hr/dL (Mean) |
|---|---|
| Inosine Fed | 36.1 |
| Inosine Fasted | 39.3 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | mg/dL (Mean) |
|---|---|
| Inosine Fed | 1.73 |
| Inosine Fasted | 1.65 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | hr (Mean) |
|---|---|
| Inosine Fed | 44.3 |
| Inosine Fasted | 44.7 |
Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 h pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose
| Intervention | hr (Median) |
|---|---|
| Inosine Fed | 3.0 |
| Inosine Fasted | 3.0 |
(NCT02614469)
Timeframe: -12 to 0 hrs pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hrs post-dose
| Intervention | mg/dL (Mean) |
|---|---|
| Inosine Fed | 6.6 |
| Inosine Fasted | 6.4 |
Number of participants with clinically significant findings in vital signs by investigator after study drug administration. (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1
| Intervention | participants (Number) |
|---|---|
| Inosine Fed | 0 |
| Inosine Fasted | 0 |
Number of participants with adverse events after study drug administration (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1
| Intervention | participants (Number) |
|---|---|
| Inosine Fed | 0 |
| Inosine Fasted | 0 |
(NCT02614469)
Timeframe: -12 to 0 pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | hr (Mean) |
|---|---|
| Inosine Fed | 242 |
| Inosine Fasted | 241 |
(NCT02614469)
Timeframe: -12 to 0 hr pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose
| Intervention | hr (Median) |
|---|---|
| Inosine Fed | 3.0 |
| Inosine Fasted | 3.0 |
1 review available for uric acid and Menopause
| Article | Year |
|---|---|
Gout in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnostic Errors; Female; Gout; Gout Suppressants; Humans; | 2009 |
5 trials available for uric acid and Menopause
| Article | Year |
|---|---|
Effect of Fermented Soymilk-Honey from Different Probiotics on Osteocalcin Level in Menopausal Women.
Topics: Aged; Blood Glucose; Cholesterol; Female; Fermentation; Honey; Humans; Lacticaseibacillus casei; Lac | 2021 |
Effect of natural oestrogen/gestagen therapy on uric acid metabolism in post-menopausal women.
Topics: Adult; Bendroflumethiazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Estrad | 1983 |
The effect of chlorothiazide on bone-related biochemical variables in normal post-menopausal women.
Topics: Acid-Base Equilibrium; Aged; Biomarkers; Body Weight; Bone Resorption; Calcium; Chlorothiazide; Crea | 1993 |
The effect of menopause on serum uric acid levels in non-obese healthy women.
Topics: Adult; Body Mass Index; Female; Humans; Insulin Resistance; Menopause; Middle Aged; Obesity; Referen | 1998 |
Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome.
Topics: Absorptiometry, Photon; Adipose Tissue; Adrenal Gland Neoplasms; Adult; Aging; Blood Pressure; Body | 2001 |
47 other studies available for uric acid and Menopause
| Article | Year |
|---|---|
Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach.
Topics: Adult; Aged; Animals; Apolipoprotein E2; Asian People; Female; Genetic Association Studies; Haplotyp | 2021 |
The Mediation Effect of Body Composition on the Association Between Menopause and Hyperuricemia: Evidence From China National Health Survey.
Topics: Body Composition; China; Female; Health Surveys; Humans; Hyperuricemia; Menopause; Uric Acid | 2022 |
Changes in cardiovascular disease risk factors during menopausal transition in Japanese women: the Circulatory Risk in Communities Study (CIRCS).
Topics: Alanine Transaminase; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; East Asian People; Fem | 2023 |
Uric acid level in climacteric women and its association with clinical and metabolic parameters.
Topics: Anthropometry; Blood Pressure; Female; Humans; Menopause; Metabolic Syndrome; Uric Acid | 2023 |
Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Liver; Liver Cirrhosis; Male; Menopause; Middle Aged; Non | 2023 |
Combined effect of serum gamma-glutamyltransferase and uric acid on incidence of diabetes mellitus: A longitudinal study.
Topics: Biomarkers; Blood Chemical Analysis; Diabetes Mellitus; Female; Follow-Up Studies; gamma-Glutamyltra | 2017 |
Urate and the risk of Parkinson's disease in men and women.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Female; | 2018 |
Association between serum uric acid and lumbar spine bone mineral density in peri- and postmenopausal Japanese women.
Topics: Aged; Aging; Bone Density; Female; Humans; Lumbar Vertebrae; Menopause; Middle Aged; Osteoporosis, P | 2014 |
Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women.
Topics: Adult; Aged; Aging; Body Mass Index; Cross-Sectional Studies; Diuretics; Female; Glomerular Filtrati | 2014 |
Oxidative stress and menopause-related hot flashes may be independent events.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Advanced Oxidation Protein Products; Antioxidants; Aryldialkylphosphata | 2015 |
Relationship between equol producer status and metabolic parameters in 743 Japanese women: equol producer status is associated with antiatherosclerotic conditions in women around menopause and early postmenopause.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Aging; Arachidonic Acid; C-Reactive Protein; Collage | 2017 |
Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey.
Topics: Adult; Estrogen Replacement Therapy; Female; Humans; Menopause; Middle Aged; Uric Acid | 2008 |
Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine.
Topics: Cross-Sectional Studies; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Humans; Meno | 2008 |
Menopausal symptoms and the metabolic syndrome in Nigerian women with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Arthralgia; Body Mass Index; Cholesterol, HDL; Cross-Sectional Studi | 2011 |
Relationship between uric acid and metabolic syndrome according to menopausal status.
Topics: Adult; Aged; Blood Pressure; Cross-Sectional Studies; Female; Health Status; Humans; Hyperuricemia; | 2011 |
Reproductive factors and serum uric acid levels in females from the general population: the KORA F4 study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Contraception Behavior; Cross-Sectiona | 2012 |
Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality.
Topics: Adult; Cardiovascular Diseases; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Hype | 2013 |
Serum total antioxidant status, erythrocyte superoxide dismutase and whole-blood glutathione peroxidase activities in the Stanislas cohort: influencing factors and reference intervals.
Topics: Adolescent; Adult; Age Factors; Aged; Albumins; Alcohol Drinking; Antioxidants; Bilirubin; Child; Ch | 2003 |
MEASUREMENT OF SERUM URIC ACID IN GREAT BRITAIN IN 1963.
Topics: Blood Chemical Analysis; Colorimetry; Female; Freeze Drying; Gout; Humans; Menopause; Sex; Spectroph | 1964 |
[The features of uric acid metabolism in women in climacterium].
Topics: Adolescent; Adult; Aged; Circadian Rhythm; Female; Humans; Hyperuricemia; Kidney Diseases; Male; Men | 2005 |
[Effect of sex steroids in vivo and in vitro on the binding of uric acid to plasma proteins].
Topics: Adult; Blood Proteins; Female; Gonadal Steroid Hormones; Humans; Male; Menopause; Menstruation; Uric | 1984 |
The effects of fasting on serum and urinary gonadotropins in obese postmenopausal women.
Topics: Acetoacetates; Adult; Fasting; Female; Follicle Stimulating Hormone; Humans; Kinetics; Luteinizing H | 1980 |
Personal and familial factors in cholesterolemia: criteria for selection of a reference population.
Topics: Adult; Age Factors; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Contr | 1980 |
Factors influencing the serum uric acid level. A study based on a population survey in Hisayama town, Kyushu, Japan.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Cholesterol; Creatinine; Female; Health Surveys; Hum | 1980 |
[The effects of aging on renal function test].
Topics: Adult; Aged; Aging; Blood Urea Nitrogen; Creatinine; Female; Humans; Kidney Function Tests; Menopaus | 1994 |
Social and biological predictors of early menopause: a model for premature aging.
Topics: Adult; Aging; Blood Glucose; Blood Pressure; Body Mass Index; Creatinine; Denmark; Female; Health St | 1997 |
[The role of insulin resistance in the clustering of cardiovascular risk factors].
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; China; Cluster Analysis; Coronary Disease; Female; Hu | 1997 |
Clinical manifestations of Korean female gouty patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Cyclosporine; Diuretics; Female; Gout; Gra | 2000 |
Relationship of relevant factors of atherosclerosis to menopause in Japanese women.
Topics: Adult; Arteriosclerosis; Cholesterol; Female; Hemoglobinometry; Humans; Japan; Menopause; Middle Age | 1979 |
The relationship of sex steroids to uric acid levels in plasma and urine.
Topics: Adolescent; Adult; Amenorrhea; Androgens; Estrogens; Female; Gonadal Steroid Hormones; Humans; Male; | 1977 |
Some theory of reference values. I. Stratified (categorized) normal ranges and a method for following an individual's clinical laboratory values.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Analysis of Variance; Chemistry, Clinical; Cholester | 1975 |
Relation between serum uric acid and angiographically defined coronary artery disease in postmenopausal women.
Topics: Aged; Coronary Angiography; Coronary Disease; Female; Humans; Male; Menopause; Middle Aged; Triglyce | 1992 |
Female gout. Clinical spectrum and uric acid metabolism.
Topics: Adult; Age Factors; Diuretics; Female; Gout; Humans; Hypertension; Kidney Failure, Chronic; Male; Me | 1991 |
Blood pressure, metabolic variables and adipose tissue distribution in pre- and post-menopausal women.
Topics: Adipose Tissue; Adult; Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans | 1990 |
Endocrine and metabolic effects of simple hysterectomy.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Cholesterol; Climacteric; Estradiol; Female; Gonadotrop | 1987 |
Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study.
Topics: Age Factors; Cholesterol; Coronary Disease; Diabetes Complications; Female; Fibrinogen; Humans; Lipi | 1987 |
The sex steroids influence on uric acid binding to human plasma proteins.
Topics: Adolescent; Adult; Allopurinol; Blood Proteins; Child; Child, Preschool; Female; Gout; Humans; Male; | 1986 |
The clinical spectrum of gouty arthritis in women.
Topics: Adult; Age Factors; Aged; Arthritis; Diuretics; Female; Gout; Humans; Kidney Diseases; Male; Menopau | 1986 |
Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate.
Topics: Absorption; Adult; Age Factors; Biological Transport; Estradiol; Female; Humans; Kidney; Male; Menop | 1986 |
[Incidence of primary hyperuricemia in ambulant patients (author's transl)].
Topics: Adult; Age Factors; Aged; Ambulatory Care; Blood Protein Disorders; Diabetes Mellitus; Female; Germa | 1974 |
Patterns of change for various biochemical constituents detected in well population screening.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Blood Chemic | 1972 |
Some contributions to metabolic relationships of uric acid.
Topics: Cholesterol; Female; Gout; Humans; Hypothyroidism; Lactates; Male; Menopause; Sex Factors; Thyroid H | 1972 |
[Gout in women].
Topics: Adult; Age Factors; Female; Gout; Humans; Kidney Diseases; Male; Menopause; Middle Aged; Obesity; Se | 1972 |
[Normal values of plasma uric acid in South Germany. Comparison with determinations made ten years ago (author's transl)].
Topics: ABO Blood-Group System; Adolescent; Adult; Aging; Blood Donors; Body Weight; Diet; Dietary Proteins; | 1973 |
Stress and coronary heart disease.
Topics: Adult; Blood Pressure; Cholesterol; Coronary Disease; Employment; Female; Humans; Male; Mass Screeni | 1971 |
[Gout in women].
Topics: Adolescent; Adult; Age Factors; Aged; Blood Pressure; Calculi; Female; Germany, West; Gout; Humans; | 1968 |
The clinical differentiation of lead gout from primary gout.
Topics: Alcohol Drinking; Body Height; Body Weight; Child Behavior Disorders; Diagnosis, Differential; Envir | 1968 |